IRADIMED CORP · Surgical & Medical Instruments & Apparatus

IRMD

Low riskNext report: Due any day

View price ↗

The short version

A high-quality, profitable business with steady sales. Institutions are adding.

Going well

Profitable every year for 10 years
Sales up 14% last year
Brings in more cash than it spends

Money moves

No insider buying or selling in the last 30 days
Institutions added 3% to their holdings in the quarter ending June 2026 (115 bought, 90 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$84.57-1.4% that day

Company value: $1.1B; Share price times all shares
Price vs profit (P/E): 47.2x; You pay about $47 for each $1 of yearly profit
Price vs sales: 12.5x; Company value is 12.5 times a year of sales
Cash vs value: 5%; Cash as a share of company value

From IRMD's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$20.5M+0.3% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $86.3M, up 11% from the 12 months before. Over 5 years, sales grew about 22% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of IRMD. Starting points are the company's recent numbers.

Sales growth+11% a yearRecently: +11% a yearProfit margin27%Last 12 months: 26.7%P/E at the end40xToday: 47.2x. Many steady companies trade at 12x to 25xShare count change+1% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$145M

Profit in 5 years$39M

Price these guesses point to$116.92+38% vs $84.57 todayAbout +6.7% a year, before dividends

What today's price needs: with a 27% margin and a 40x P/E, sales would have to grow about 4.0% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

6/7Strong

PassReturn on equity 15%+Earns a lot on the money owners have in the business.24.8%
PassDebt under half of equityNot relying on borrowed money.No debt reported
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.26.8%
PassProfitable every yearSteady profits, not one good year.10 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$17.2M
MissShare count not growingNot diluting owners. Falling means buybacks.+1.7% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.76.7%

Revenue: $83.8M; +14.4% vs prior year
5-year growth: +21.5%/yr; revenue, per year
Total debt: None; 0.00x equity
Current ratio: 7.98x; short-term assets / bills due

From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.